Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013)

Cervantes F.; Vannucchi A. M.; Kiladjian J-J

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013)

【24h】

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013)

机译：COMFORT-II的三年疗效，安全性和生存期研究结果，这是一项将鲁索替尼与最佳可行的骨髓纤维化疗法进行比较的3期研究（第122卷，第4047页，2013年）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2016年第25期| 共1页
作者
Cervantes F.; Vannucchi A. M.; Kiladjian J-J;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013) [J] . Cervantes F., Vannucchi A. M., Kiladjian J-J Blood: The Journal of the American Society of Hematology . 2016 ,第25期

机译：COMFORT-II的三年疗效，安全性和生存期研究结果，这是一项将鲁索替尼与最佳可行的骨髓纤维化疗法进行比较的3期研究（第122卷，第4047页，2013年）
2. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013) [J] . Cervantes F., Vannucchi A. M., Kiladjian J-J Blood: The Journal of the American Society of Hematology . 2016 ,第25期

机译：COMFORT-II的三年疗效，安全性和生存期研究结果，这是一项将鲁索替尼与最佳可行的骨髓纤维化疗法进行比较的3期研究（第122卷，第4047页，2013年）
3. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [J] . CervantesF., VannucchiA.M., KiladjianJ.-J., Blood: The Journal of the American Society of Hematology . 2013 ,第25期

机译：来自COMFORT-II的三年疗效，安全性和生存结果，这是一项将鲁索替尼与骨髓纤维化的最佳可用疗法进行比较的3期研究
4. Transcranial near infrared laser therapy (NILT) to treat acute ischemic stroke: a review of efficacy, safety and possible mechanism of action derived from rabbit embolic stroke studies [C] . Paul A. Lapchak, Jackson Streeter, Luis De Taboada Mechanisms for low-light therapy V . 2010

机译：经颅近红外激光治疗急性缺血性中风：兔栓塞性中风研究的疗效，安全性和可能的作用机制综述
5. A dose finding method in joint modeling of efficacy and safety endpoints in phase II studies - an extension of the MCP-MOD method. [D] . Tao, Aiyang. 2010

机译：II期研究中疗效和安全性终点联合建模中的一种剂量寻找方法-MCP-MOD方法的扩展。
6. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis [O] . Mary Frances McMullin, Claire N. Harrison, Dietger Niederwieser, 2015

机译：ruxolitinib促红细胞生成素促进剂在COMFORT-II骨髓纤维化患者中的应用：一项开放性的3期研究评估ruxolitinib相对于最佳治疗骨髓纤维化的疗效和安全性
7. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [O] . F. Cervantes, A. M. Vannucchi, J.-J. Kiladjian, 2013

机译：COmFORT-II的三年疗效，安全性和生存率调查结果，这是一项将ruxolitinib与骨髓纤维化最佳治疗方案进行比较的3期研究

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013)

著录项

相似文献

相关主题

期刊订阅